Arrowhead Research Corporation — Rendiconto Finanziario Trimestrale (NASDAQ:ARWR)

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Market Capitalization 9.9353 B
Employee 711
Founded 2004
CEO Christopher Richard Anzalone
Website www.arrowheadpharma.com
Headquarter Delaware, United States
FIGI BBG000BRVKH0
Industry Technology

Ricavi totali

Utile netto

Utile base per azione (EPS base)

Debito totale

Liquidità libera

Disponibilità liquide e mezzi equivalenti

9.94 B Capitalizzazione di mercato

Rapporto prezzo/utili

41.49

Rapporto prezzo/fatturato

8.27

Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.

ARWR

Financials

Arrowhead Pharmaceuticals Inc

Notizie

TD Cowen conferma rating Buy su Arrowhead Pharma

BofA riduce il target di prezzo di Arrowhead Pharma per l’obesità

Wave Life Sciences Crashes 55% As 'Body Composition' Fat-Loss Drug Underwhelms

Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead (NASDAQ:ARWR)

Leerink conferma il rating su Arrowhead Pharma dopo i dati del partner

Wolfe Research conferma il rating su Ionis per la strategia di prezzo

Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies

SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study

Hamilton James, CMO di Arrowhead Pharmaceuticals, vende azioni per 641.900 dollari

Arrowhead Pharmaceuticals alla Conferenza Leerink: Approfondimenti Strategici sulla Pipeline

Arrowhead Pharmaceuticals at Leerink Conference: Strategic Pipeline Insights

Arrowhead Pharmaceuticals alla TD Cowen Conference: focus cardiometabolico